Skip to NavigationSkip to content

Top Ten most popular articles on this week!

Published on 08/03/19 at 10:25am

HIV hit the headlines this week after it was announced that a British man known only as the ‘London Patient’ had been cured of HIV after receiving a bone marrow transplant from a donor with natural resistance to the immunodeficiency virus. Meanwhile Gilead offered positive results with HIV drug Biktarvy.

The news comes as sources told Reuters OxyContin drugmaker Purdue Pharma was exploring bankruptcy as a get out for the lawsuits they face over their role in manufacturing the opioid crisis.

The big news of this week however was the fact that FDA Commissioner Scott Gottlieb announced he would be stepping down from his role as head of the US regulator in the first week of May.

10. Novartis' Cosentyx tops Janssen's Stelara in moderate-to-severe psoriasis trial

New data has been revealed in support of Novartis’ Cosentyx (secukinumab) in the treatment of moderate-to-severe plaque psoriasis, demonstrating the drug delivered greater quality of life improvements compared to Janssen’s Stelara (ustekinumab) after 16 weeks of treatment.

9. Biogen boosts ophthalmology portfolio with $800m acquisition of gene therapy firm Nightstar

Biogen has announced it has inked an agreement to acquire clinical-stage gene therapy firm Nightstar for a total value of $800 million, which breaks down to $2.50 in cash per share after transaction expenses are taken into account. 

8. Gilead's Biktarvy maintains HIV suppression for 48 weeks in children and adolescents

Gilead has lifted the curtain on new Phase 2/3 efficacy data for Biktarvy, revealing that the drug demonstrated high efficacy in maintaining virologic suppression in already virologically suppressed adolescents and children aged six years and older living with HIV.

7. London man becomes second in world to be cured of HIV

A man in Britain has become the second person to be ‘cured’ of HIV, after receiving a bone marrow transplant from a donor with natural resistance to the virus.

6. OxyContin drugmaker Purdue Pharma exploring bankruptcy, sources say

OxyContin drugmaker Purdue Pharma is exploring the option of filing for bankruptcy. The news comes as the Connecticut-based firm faces thousands of lawsuits over allegations the company’s actions contributed to the opioid crisis in the United States.

5. Novartis set to offer 14 weeks paternity leave

Novartis is planning to offer employees 14 weeks of parental leave, a move which would make the firm one of the most generous in Switzerland.

4. Indian government set to colour code generic medicines

As part of an effort to promote low cost medicines the Indian government has announced plans to colour code generic drugs.

3. Feature: The cutting edge of cancer research

 While immunotherapies continue to be the darling of the industry, new, innovative and sometimes seemingly fantastical research is emerging that blurs the realms of possibility in cancer treatment, Matt Fellows discovers.

2. AbbVie's Skyrizi scoops up CHMP recommendation for moderate to severe plaque psoriasis

AbbVie’s interleukin-23 (IL-23) inhibitor Skyrizi (risankizumab) has secured recommendation from the EMA’s Committee for Medicinal Products for Human Use (CHMP), it has emerged.

1. FDA Commissioner Scott Gottlieb announces resignation

Dr Scott Gottlieb, the 23rd Commissioner of the US Food and Drug Administration (FDA), stoked surprise throughout the industry with the announcement of his sudden resignation from the post in the first week of May.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches